The effect of clozapine on factors controlling glucose homeostasis

O D Howes; F P Gaughran; S A Amiel; R M Murray; L S Pilowsky

doi:10.4088/JCP.v65n1009

The effect of clozapine on factors controlling glucose homeostasis

O D Howes, F P Gaughran, S A Amiel, R M Murray, L S Pilowsky

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Background: This prospective study examines the effect of clozapine on factors determining glucose homeostasis. Method: The sample consisted of all patients meeting DSM-IV criteria for schizophrenia who commenced clozapine treatment within the South London and Maudsley hospitals during I year (2000-2001). Growth hormone (GH), insulin-like growth factor-1 (IGF-1), and IGF binding protein-1 (IGFBP- 1) were measured in 19 patients (10 female; mean age = 31.1 years [SD = 5.8]; 9 black British/African, 10 white British) before and after a mean of 2.5 (SD = 0.9) months of clozapine treatment. Results: Baseline IGFBP-1 was low. IGFBP-1, GH, and IGF-1 were not significantly changed by clozapine treatment. Conclusions: Clozapine does not alter GH, 1GF-1, or IGFBP-1 within 3 months of commencing treatment, indicating that alteration in glucose tolerance associated with clozapine treatment involves other mechanisms yet to be elucidated. Baseline abnormalities in IGFBP-1 indicate a preexisting susceptibility to glucoregulatory dysfunction.

Original language	English
Pages (from-to)	1352 - 1355
Number of pages	4
Journal	Journal of Clinical Psychiatry
Volume	65
Issue number	10
DOIs	https://doi.org/10.4088/JCP.v65n1009
Publication status	Published - Oct 2004

Access to Document

10.4088/JCP.v65n1009

Cite this

@article{a6e12117ae564cb4994baa897d13b2ac,

title = "The effect of clozapine on factors controlling glucose homeostasis",

abstract = "Background: This prospective study examines the effect of clozapine on factors determining glucose homeostasis. Method: The sample consisted of all patients meeting DSM-IV criteria for schizophrenia who commenced clozapine treatment within the South London and Maudsley hospitals during I year (2000-2001). Growth hormone (GH), insulin-like growth factor-1 (IGF-1), and IGF binding protein-1 (IGFBP- 1) were measured in 19 patients (10 female; mean age = 31.1 years [SD = 5.8]; 9 black British/African, 10 white British) before and after a mean of 2.5 (SD = 0.9) months of clozapine treatment. Results: Baseline IGFBP-1 was low. IGFBP-1, GH, and IGF-1 were not significantly changed by clozapine treatment. Conclusions: Clozapine does not alter GH, 1GF-1, or IGFBP-1 within 3 months of commencing treatment, indicating that alteration in glucose tolerance associated with clozapine treatment involves other mechanisms yet to be elucidated. Baseline abnormalities in IGFBP-1 indicate a preexisting susceptibility to glucoregulatory dysfunction.",

author = "Howes, {O D} and Gaughran, {F P} and Amiel, {S A} and Murray, {R M} and Pilowsky, {L S}",

year = "2004",

month = oct,

doi = "10.4088/JCP.v65n1009",

language = "English",

volume = "65",

pages = "1352 -- 1355",

journal = "Journal of Clinical Psychiatry",

publisher = "Physicians Postgraduate Press Inc.",

number = "10",

}

TY - JOUR

T1 - The effect of clozapine on factors controlling glucose homeostasis

AU - Howes, O D

AU - Gaughran, F P

AU - Amiel, S A

AU - Murray, R M

AU - Pilowsky, L S

PY - 2004/10

Y1 - 2004/10

N2 - Background: This prospective study examines the effect of clozapine on factors determining glucose homeostasis. Method: The sample consisted of all patients meeting DSM-IV criteria for schizophrenia who commenced clozapine treatment within the South London and Maudsley hospitals during I year (2000-2001). Growth hormone (GH), insulin-like growth factor-1 (IGF-1), and IGF binding protein-1 (IGFBP- 1) were measured in 19 patients (10 female; mean age = 31.1 years [SD = 5.8]; 9 black British/African, 10 white British) before and after a mean of 2.5 (SD = 0.9) months of clozapine treatment. Results: Baseline IGFBP-1 was low. IGFBP-1, GH, and IGF-1 were not significantly changed by clozapine treatment. Conclusions: Clozapine does not alter GH, 1GF-1, or IGFBP-1 within 3 months of commencing treatment, indicating that alteration in glucose tolerance associated with clozapine treatment involves other mechanisms yet to be elucidated. Baseline abnormalities in IGFBP-1 indicate a preexisting susceptibility to glucoregulatory dysfunction.

AB - Background: This prospective study examines the effect of clozapine on factors determining glucose homeostasis. Method: The sample consisted of all patients meeting DSM-IV criteria for schizophrenia who commenced clozapine treatment within the South London and Maudsley hospitals during I year (2000-2001). Growth hormone (GH), insulin-like growth factor-1 (IGF-1), and IGF binding protein-1 (IGFBP- 1) were measured in 19 patients (10 female; mean age = 31.1 years [SD = 5.8]; 9 black British/African, 10 white British) before and after a mean of 2.5 (SD = 0.9) months of clozapine treatment. Results: Baseline IGFBP-1 was low. IGFBP-1, GH, and IGF-1 were not significantly changed by clozapine treatment. Conclusions: Clozapine does not alter GH, 1GF-1, or IGFBP-1 within 3 months of commencing treatment, indicating that alteration in glucose tolerance associated with clozapine treatment involves other mechanisms yet to be elucidated. Baseline abnormalities in IGFBP-1 indicate a preexisting susceptibility to glucoregulatory dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=16544363627&partnerID=8YFLogxK

U2 - 10.4088/JCP.v65n1009

DO - 10.4088/JCP.v65n1009

M3 - Article

VL - 65

SP - 1352

EP - 1355

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

IS - 10

ER -

The effect of clozapine on factors controlling glucose homeostasis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this